Novo Nordisk (NVO) Hit By Lowered Guidance

GreensKeeper Asset Management, an investment management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Value Fund has ended the quarter with a +4.0% gain, taking the YTD return to +0.2% net of fees and expenses. The US dollar continued to pose a challenge, negatively impacting performance by -3.7% so far this year. The year’s market rally was primarily led by AI, crypto, and speculation. In addition, you can check the fund’s top 5 holdings to determine its best picks for 2025.

In its third-quarter 2025 investor letter, GreensKeeper Asset Management highlighted stocks such as Novo Nordisk A/S (NYSE:NVO). Novo Nordisk A/S (NYSE:NVO) engages in the research and development, manufacture, and distribution of pharmaceutical products. The one-month return of Novo Nordisk A/S (NYSE:NVO) was -0.08%, and its shares lost 53.79% of their value over the last 52 weeks. On December 16, 2025, Novo Nordisk A/S (NYSE:NVO) stock closed at $48.96 per share, with a market capitalization of $217.553 billion.

GreensKeeper Asset Management stated the following regarding Novo Nordisk A/S (NYSE:NVO) in its third quarter 2025 investor letter:

“Our second-largest detractor in the quarter was Novo Nordisk A/S (NYSE:NVO) -19.6%. NVO lowered its guidance due to several factors, including persistent use of compounded GLP-1 medications, slower-than-expected market expansion for obesity treatments, and heightened competition from Eli-Lilly’s tirzepatide-based therapies. We welcome the recently announced changes to senior management and the company’s new focus on operating efficiency.

We believe more vigorous enforcement against illicit drug compounding is emerging, providing a tailwind for NVO’s earnings. Longer term, we believe the company’s drug pipeline is better than the market is giving them credit for and that the obesity market will continue to expand as GLP-1 therapies gain broader indications, introduce oral versions, and payer coverage improves.”

Novo Nordisk A/S (NYSE:NVO) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 50 hedge fund portfolios held Novo Nordisk A/S (NYSE:NVO) at the end of the third quarter, which was 45 in the previous quarter. While we acknowledge the risk and potential of Novo Nordisk A/S (NYSE:NVO) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than NOVO NORDISK A/S (NYSE:NVO) and that has 10,000% upside potential, check out our report about this cheapest AI stock.

In another article, we covered Novo Nordisk A/S (NYSE:NVO) and shared the list of best ADR stocks to invest in. In addition, please check out our hedge fund investor letters Q3 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.